UBS Group Initiates Coverage on Jasper Therapeutics (NASDAQ:JSPR)

UBS Group began coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report issued on Thursday, Marketbeat reports. The brokerage issued a buy rating and a $38.00 price target on the stock.

A number of other equities research analysts have also recently weighed in on the stock. HC Wainwright decreased their target price on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, January 10th. BMO Capital Markets assumed coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. Royal Bank of Canada lowered their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research note on Thursday, January 9th. Finally, JMP Securities reissued a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research note on Monday, January 6th. Eleven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $64.44.

Jasper Therapeutics Price Performance

NASDAQ:JSPR opened at $6.20 on Thursday. The firm’s 50-day moving average price is $13.12 and its 200-day moving average price is $17.63. The company has a market capitalization of $93.01 million, a PE ratio of -1.31 and a beta of 2.11. Jasper Therapeutics has a 1-year low of $4.55 and a 1-year high of $31.01.

Hedge Funds Weigh In On Jasper Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of JSPR. BNP Paribas Financial Markets lifted its holdings in Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after acquiring an additional 1,698 shares during the period. Wolff Wiese Magana LLC purchased a new stake in shares of Jasper Therapeutics during the 3rd quarter valued at about $59,000. MetLife Investment Management LLC lifted its stake in shares of Jasper Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after purchasing an additional 3,873 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Jasper Therapeutics by 106.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after buying an additional 3,828 shares during the last quarter. Finally, EntryPoint Capital LLC bought a new stake in Jasper Therapeutics during the fourth quarter valued at approximately $223,000. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.